NDA 016320 · Kanchan Hlthcare
Myambutol
Ethambutol Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 22, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1967
Nov 6, 1967
Approved uses
1
Original approval plus efficacy supplements
Registered trials
180
52 Phase 3, 27 recruiting
FAERS reports
2,718
2,227 serious, 334 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 5, 2026.
INDICATIONS ETHAMBUTOL HCl is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. In patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ETHAMBUTOL HCl plus isoniazidETHAMBUTOL HCl plus isoniazid plus streptomycin. In patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. Consequently, in such retreatment patients, ETHAMBUTOL HCl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. Antituberculous drugs used with ETHAMBUTOL HCl have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilized.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 6, 1967 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
- MYAMBUTOL · ETHAMBUTOL HYDROCHLORIDE 200MG · TABLET, ORAL · Discontinued
- MYAMBUTOL · ETHAMBUTOL HYDROCHLORIDE 400MG · TABLET, ORAL · Prescription · TE AB
- MYAMBUTOL · ETHAMBUTOL HYDROCHLORIDE 100MG · TABLET, ORAL · Prescription · TE AB
- MYAMBUTOL · ETHAMBUTOL HYDROCHLORIDE 500MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethambutol" as an intervention, any sponsor and status, largest first.
- Shortened Regimens for Drug-susceptible Pulmonary TuberculosisPivotal-lookingStatus unknown
Beijing Chest HospitalAcademic, hospital or other
NCT02901288 · 3,900 participants (planned) · Start Aug 2016 · Primary completion Dec 2018
Drug: Isoniazid; Rifampicin and 3 more · For: Tuberculosis, Pulmonary
Sites: Hefei, China; Beijing, China; Chongqing, China · 35 sites in all
- TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening RegimensPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT02410772 · 2,516 participants · Start Jan 25, 2016 · Primary completion Jul 2020
Drug: rifapentine; rifapentine and moxifloxacin and 1 more · For: Tuberculosis
Sites: San Francisco, California; New York, New York; Fort Worth, Texas · 33 sites in all
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of TuberculosisPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT02563327 · 2,516 participants · Start Jan 25, 2016 · Primary completion Aug 30, 2021
Drug: Rifapentine; Moxifloxacin and 4 more · For: Tuberculosis
Sites: San Antonio, Texas; Kampala, Uganda; Hanoi, Vietnam
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
- A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without LevofloxacinPivotal-lookingRecruiting
Tuberculosis Research Centre, IndiaGovernment (non-federal)
NCT07947056 · 2,500 participants (planned) · Start Jun 6, 2026 · Primary completion Dec 2028
Drug: Standard 6-month treatment regimen; High dose Rifampicin (25mg/Kg) and 2 more · For: Tuberculosis, Pulmonary, Drug Sensitive
Sites: Guntur, India; Guwahati, India; Rajkot, India · 15 sites in all
- Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary TuberculosisPivotal-lookingCompleted
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
NCT00864383 · 1,931 participants · Start Jan 2008 · Primary completion Oct 2013
Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin · For: Pulmonary Tuberculosis
Sites: Beijing, China; Shanghai, China; Tianjin, China · 47 sites in all
- Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune SuppressionPivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT04738812 · 1,330 participants · Start Apr 21, 2022 · Primary completion Nov 12, 2025
Drug: Intensified TB treatment (initial phase); WHO standard TB treatment (initial phase) · For: Tuberculosis; HIV-1-infection; Immuno-Deficiency
Sites: Phnom Penh, Cambodia; Yaoundé, Cameroon; Conakry, Guinea · 6 sites in all
- A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2Pivotal-lookingStatus unknown
Beijing Chest HospitalAcademic, hospital or other
NCT04766307 · 1,100 participants (planned) · Start Jul 20, 2016 · Primary completion Dec 31, 2021
Drug: Interleukin-2 · For: Tuberculosis, Pulmonary
Sites: Fuyang, China; Fuzhou, China; Shenzhen, China · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use in unapproved indication215
- pyrexia168
- nausea134
- vomiting126
- drug interaction116
- drug intolerance106
- cough95
- off label use95
- dyspnoea93
- diarrhoea89
- immune reconstitution syndrome86
- mycobacterium avium complex infection84
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 12 |
| 2006 | 59 |
| 2007 | 161 |
| 2008 | 117 |
| 2009 | 76 |
| 2010 | 162 |
| 2011 | 196 |
| 2012 | 198 |
| 2013 | 25 |
| 2014 | 33 |
| 2015 | 16 |
| 2016 | 16 |
| 2017 | 39 |
| 2018 | 50 |
| 2019 | 60 |
| 2020 | 81 |
| 2021 | 80 |
| 2022 | 205 |
| 2023 | 320 |
| 2024 | 293 |
| 2025 | 317 |
| 2026 | 192 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis.
Schwab TC, Perrig L, Göller PC, et al. · Lancet Infect Dis 2024 · Systematic Review, Meta-Analysis
- Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.
Meya DB, Cresswell FV, Dai B, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Tuberculosis (TB) treatment challenges in TB-diabetes comorbid patients: a systematic review and meta-analysis.
Khattak M, Rehman AU, Muqaddas T, et al. · Ann Med 2024 · Meta-Analysis, Systematic Review
- Tuberculosis (HIV-negative people).
Ziganshina LE, Garner P · BMJ Clin Evid 2009 · Systematic Review
Sponsor: Kanchan Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.